Cheng CH, Hao WR, Cheng TH. Role of intestinal glucagon-like peptide-1 in hypoglycemia response impairment in type 1 diabetes. World J Diabetes 2024; 15(11): 2237-2241 [DOI: 10.4239/wjd.v15.i11.2237]
Corresponding Author of This Article
Tzu-Hurng Cheng, PhD, Professor, Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, No. 91 Xueshi Road, North District, Taichung City 404328, Taiwan. thcheng@mail.cmu.edu.tw
Research Domain of This Article
Medicine, Research & Experimental
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Diabetes. Nov 15, 2024; 15(11): 2237-2241 Published online Nov 15, 2024. doi: 10.4239/wjd.v15.i11.2237
Role of intestinal glucagon-like peptide-1 in hypoglycemia response impairment in type 1 diabetes
Chun-Han Cheng, Wen-Rui Hao, Tzu-Hurng Cheng
Chun-Han Cheng, Department of Medical Education, Linkou Chang Gung Memorial Hospital, Taoyuan City 33305, Taiwan
Wen-Rui Hao, Division of Cardiology, Department of Internal Medicine, Shuang Ho Hospital, Ministry of Health and Welfare, Taipei Medical University, New Taipei City 23561, Taiwan
Wen-Rui Hao, Division of Cardiology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11002, Taiwan
Tzu-Hurng Cheng, Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, Taichung City 404328, Taiwan
Co-first authors: Chun-Han Cheng and Wen-Rui Hao.
Author contributions: Cheng CH and Hao WR contribute equally to this study as co-first authors. Cheng CH, Hao WR, and Cheng TH have contributed to this study, with Cheng CH and Hao WR primarily responsible for writing, and Cheng TH overseeing revisions; all authors have read and approved the final manuscript.
Conflict-of-interest statement: All authors declare having no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Tzu-Hurng Cheng, PhD, Professor, Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, No. 91 Xueshi Road, North District, Taichung City 404328, Taiwan. thcheng@mail.cmu.edu.tw
Received: July 10, 2024 Revised: September 17, 2024 Accepted: October 8, 2024 Published online: November 15, 2024 Processing time: 97 Days and 15.3 Hours
Abstract
This study critically examines the novel findings presented by Jin et al, which explores the role of intestinal glucagon-like peptide-1 (GLP-1) in impaired counterregulatory responses to hypoglycemia in mice with type 1 diabetes. The study identifies intestinal GLP-1 as a significant determinant in the physiological responses to hypoglycemia, offering new insights into its potential implications for diabetes management. The editorial synthesizes these findings, discusses their relevance in the context of current diabetes research, and outlines potential avenues for future investigation of intestinal GLP-1 as a therapeutic target. This analysis underscores the need for continued research into the complex mechanisms underlying impaired hypoglycemia responses and highlights the potential of targeting intestinal GLP-1 pathways in therapeutic strategies for type 1 diabetes.
Core Tip: Intestinal glucagon-like peptide-1 is identified as a key factor in modulating counterregulatory responses to hypoglycemia in type 1 diabetes. Gaining a deeper understanding of its role may lead to the development of innovative therapeutic strategies for enhancing hypoglycemia management in patients with diabetes.
